ORC6 marks a replication-active malignant epithelial state and is associated with immune-low features in oral squamous cell carcinoma - Scorecard - MDSpire
Advertisement
ORC6 Identifies a Malignant Epithelial State with Active Replication and Correlates with Low Immune Features in Oral Squamous Cell Carcinoma
Clinical Scorecard: ORC6 Identifies a Malignant Epithelial State with Active Replication and Correlates with Low Immune Features in Oral Squamous Cell Carcinoma
At a Glance
Category
Detail
Condition
Oral Squamous Cell Carcinoma (OSCC)
Key Mechanisms
ORC6 is involved in DNA replication licensing and is associated with adverse clinicopathological features and poorer survival.
Target Population
Patients with Oral Squamous Cell Carcinoma, particularly HPV-negative cases.
Care Setting
Clinical oncology and research settings focusing on head and neck cancers.
Key Highlights
ORC6 is upregulated in OSCC tissues and cell lines.
High ORC6 expression correlates with a replication-active malignant epithelial state.
ORC6 expression is associated with reduced immune-related features.
Knockdown of ORC6 in CAL27 cells decreases cell growth and increases antigen-presentation-related transcripts.
Guideline-Based Recommendations
Diagnosis
Utilize transcriptomic profiling to evaluate ORC6 expression in OSCC.
Management
Consider ORC6 as a potential biomarker for aggressive disease in OSCC.
Monitoring & Follow-up
Monitor immune-related features in relation to ORC6 expression levels.
Risks
Higher ORC6 levels are linked to poorer survival outcomes.
Patient & Prescribing Data
Patients diagnosed with Oral Squamous Cell Carcinoma.
Immunotherapy, particularly PD-1 inhibitors, is integrated into management for recurrent or metastatic cases.
Clinical Best Practices
Implement multimodal treatment strategies centered on surgery for OSCC.
Conduct functional immune-recognition studies to further validate ORC6's role.
